小体积前列腺指数病灶的MRI路径:单中心回顾性分析
该单中心回顾性分析纳入107例外周带小体积PI-RADS 4指数病灶(最大径≤7 mm)患者,均在多参数MRI后行MRI引导下经直肠活检。结果显示66.3%检出前列腺癌,43.9%为临床显著前列腺癌,线性/楔形病灶占50.5%且其中61.1%检出前列腺癌、48.1%为临床显著前列腺癌,提示小体积指数病灶中高级别成分比例高于既往认识,病灶大小本身不足以安全豁免活检。
要点
- 外周带≤7 mm的PI-RADS 4指数病灶中,66.3%检出前列腺癌、43.9%为临床显著前列腺癌。
- 线性/楔形病灶占50.5%,该亚组前列腺癌检出率61.1%、临床显著前列腺癌48.1%。
- 作者认为病灶大小本身不足以提供充分 reassurance 以豁免活检,小体积指数病灶不能安全忽略。
核心结论
- 小体积PI-RADS 4指数病灶中高级别(Gleason 4或5模式)成分比例高于既往认识,病灶大小本身不足以安全豁免活检;MRI引导下经直肠活检是准确取样和表征小体积指数病灶的有价值技术。
研究设计与样本
- 单中心回顾性分析,回顾2010年1月至2025年2月连续602例接受多参数MRI及后续MRI引导下经直肠前列腺活检的男性,其中107例外周带小体积PI-RADS 4指数病灶(最大径≤7 mm)构成研究队列。
诊断标准与关键数值
- 小体积指数病灶定义为外周带PI-RADS 4、最大径≤7 mm。
- 全队列前列腺癌检出率66.3%(71/107),临床显著前列腺癌检出率43.9%(47/107)。
- 线性/楔形病灶占50.5%(54/107),该亚组前列腺癌检出率61.1%(33/54)、临床显著前列腺癌检出率48.1%(26/54)。
临床应用与阅片要点
- 作者认为病灶大小本身不足以提供充分 reassurance 以豁免活检,小体积指数病灶不能安全忽略。
- 作者指出MRI引导下经直肠活检是准确取样和表征小体积指数病灶的有价值技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: By using MRI-guided in-bore biopsy, we examined the specific question of the significance of small volume index lesions that are increasingly prevalent in daily practice.
METHODS: We retrospectively reviewed 602 consecutive men who underwent multiparametric MRI (mpMRI) and subsequent MRI-guided in-bore prostate biopsy between January 2010 and February 2025. One hundred seven patients with peripheral zone (PZ) small volume PI-RADS 4 index lesions (≤7 mm in greatest dimension) comprised the study cohort. Patient age, prostate-specific antigen (PSA) level, PSA density, target size, shape (round/oval, linear/wedge, or subcapsular crescentic), International Society of Urological Pathology (ISUP) Grade Group, and tumour length to core length ratio were correlated.
RESULTS: In this cohort, the mean age, PSA, prostate volume, PSA density, and lesion size were 63.8 years (range: 45-79 years), 5.6 ng/mL (range: 1.6-18 ng/mL), 53.5 mL (range: 14-151 mL), 0.12 ng/mL2 (range: 0.02-0.43 ng/mL2) and 5.7 mm (range: 3-7 mm), respectively. A total of 107 patients were examined, of whom 71 (66.3%) were found to have prostate cancer (PCa) and 47 (43.9%) had clinically significant prostate cancer (csPCa). The percentage of linear/wedge-shaped targets was 50.5% (n = 54/107) and the detection rates of PCa and csPCa for this subgroup were 61.1% (n = 33/54) and 48.1% (n = 26/54), respectively.
CONCLUSION: Our study reveals that a higher percentage of small volume index lesions harbour a high grade (Gleason pattern 4 or 5) component than previously thought, suggesting that lesion size alone does not provide sufficient reassurance to omit biopsy. MRI-guided in-bore biopsy is a valuable technique for accurately sampling and characterizing small-volume index lesions.
ADVANCES IN KNOWLEDGE: Nearly half of the small volume index lesions on mpMRI are clinically significant regardless of their shape and these lesions cannot be safely ignored.
引用
- Vural M, Atasoy D, Durmaz S, et al. MRI pathway for small volume prostate gland index lesions: a single-centre retrospective analysis. Br J Radiol. 2026. PMID: 41212183. doi:10.1093/bjr/tqaf269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。